No connection

Search Results

FMS vs MDGL

FMS
Fresenius Medical Care AG
BULLISH
Price
$22.77
Market Cap
$12.44B
Sector
Healthcare
AI Confidence
75%
MDGL
Madrigal Pharmaceuticals, Inc.
NEUTRAL
Price
$525.67
Market Cap
$12.06B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
FMS
11.56
MDGL
--
Forward P/E
FMS
5.62
MDGL
41.09
P/B Ratio
FMS
0.81
MDGL
19.92
P/S Ratio
FMS
0.63
MDGL
12.58
EV/EBITDA
FMS
6.25
MDGL
-38.23

Profitability

Gross Margin
FMS
25.62%
MDGL
94.14%
Operating Margin
FMS
11.68%
MDGL
-18.57%
Profit Margin
FMS
4.98%
MDGL
-30.08%
ROE
FMS
7.93%
MDGL
-42.49%
ROA
FMS
3.62%
MDGL
-16.3%

Growth

Revenue Growth
FMS
-0.3%
MDGL
210.8%
Earnings Growth
FMS
420.0%
MDGL
--

Financial Health

Debt/Equity
FMS
0.76
MDGL
0.58
Current Ratio
FMS
1.26
MDGL
4.01
Quick Ratio
FMS
0.85
MDGL
3.6

Dividends

Dividend Yield
FMS
3.58%
MDGL
--
Payout Ratio
FMS
42.76%
MDGL
0.0%

AI Verdict

FMS BULLISH

FMS presents a classic deep-value opportunity, characterized by a stable Piotroski F-Score of 6/9 and a current price ($22.77) trading significantly below both its Graham Number ($35.27) and Intrinsic Value ($58.12). While top-line revenue growth is stagnant (-0.30%), the company has demonstrated a massive recovery in earnings and maintains a sustainable dividend payout ratio of 42.76%. The valuation is exceptionally attractive with a Forward P/E of 5.62 and a Price/Book of 0.81. However, the bullish value thesis is countered by a completely bearish technical trend and weak insider sentiment, suggesting a 'value trap' risk if revenue does not stabilize.

Strengths
Significant undervaluation relative to Graham Number and Intrinsic Value
Strong earnings recovery with YoY growth of 420%
Attractive valuation multiples (P/B 0.81, P/S 0.63, Forward P/E 5.62)
Risks
Stagnant revenue growth (-0.30% YoY) indicating a lack of top-line momentum
Severe bearish technical trend (0/100 score)
Low insider sentiment (40/100) suggesting lack of internal confidence
MDGL NEUTRAL

MDGL exhibits a severe disconnect between its deterministic financial health and its growth trajectory, highlighted by a critically weak Piotroski F-Score of 1/9. While the company is experiencing explosive revenue growth of 210.80% YoY, it remains deeply unprofitable with a profit margin of -30.08% and a history of significant earnings misses. The valuation is aggressive, trading at a Price/Book of 19.92, which suggests the market is pricing in substantial future success. Despite a 'Strong Buy' analyst consensus and a high price target, heavy insider selling and a bearish technical trend suggest caution.

Strengths
Exceptional revenue growth (210.80% YoY)
Strong short-term liquidity with a Current Ratio of 4.01
High gross margins (94.14%) typical of successful biotech products
Risks
Critically low Piotroski F-Score (1/9) indicating poor fundamental health
Consistent failure to meet earnings estimates (1/4 beats in last 4 quarters)
Extreme valuation premiums (P/B of 19.92 and P/S of 12.58)

Compare Another Pair

FMS vs MDGL: Head-to-Head Comparison

This page compares Fresenius Medical Care AG (FMS) and Madrigal Pharmaceuticals, Inc. (MDGL) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile